Lugano · Oncologia
Sistemas/Oncologia

Lugano Lugano classification for lymphoma response

vigente

Assesses lymphoma staging and treatment response.

Índice de referência, não é suporte à decisão clínica. O RadCommons apresenta conteúdo de referência reescrito a partir de critérios publicados e com link para a fonte primária. Confira sempre a publicação primária vigente. Não é um dispositivo médico nem substitui o julgamento clínico. O radiologista responsável pelo laudo permanece o autor e o responsável.
Escala de categorias
CMRPMRSDPMD

As figuras e tabelas estão na fonte primária. Abrir a fonte. O RadCommons reescreve e cita, não reproduz figuras protegidas por direitos autorais.

Procedência e vigência

Órgão emissor
Lymphoma imaging consensus
Versão
2014
Ano
2014
Família
léxico
Tipo de lógica
flat
Modalidade
PET, CT
Fonte primária
Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma (Lugano) · doi:10.1200/JCO.2013.54.8800
Última verificação
2026-06-22
Última checagem
2026-06-22

Lógica de decisão

Forma estruturada (flat). Uma futura calculadora a lê; as categorias abaixo são a superfície legível.

Mostrar a lógica estruturada (JSON)
{
  "categories": [
    "CMR",
    "PMR",
    "SD",
    "PMD"
  ]
}

Categorias num relance

Cat.SignificadoCondutaRiscoFonte
CMR
Complete metabolic response
Complete Metabolic Response: on FDG-PET, a Deauville 5-point score of 1, 2 or 3 (uptake at or below liver) at any residual mass, with no new FDG-avid disease; on CT, target nodes/nodal masses regress to <=1.5 cm in the longest transverse diameter, with no new lesions.
PMC4979083 (Cheson et al., 'Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification') Table 3 'Revised Criteria for Response Assessment', Complete Response row (PET 5PS score 1, 2 or 3; CT 'target nodes/nodal masses must regress to <=1.5 cm in LDi')
PMR
Partial metabolic response
Partial Metabolic Response: on FDG-PET, a Deauville score of 4 or 5 but with reduced uptake compared with baseline (and, at interim, residual masses of any size); on CT, at least a 50% decrease in the sum of the products of perpendicular diameters (SPD) of up to 6 target measurable nodes/extranodal sites, with no new lesions and no progression.
PMC4979083 Table 3 'Revised Criteria for Response Assessment', Partial Response row (PET 5PS score 4-5 with reduced uptake vs baseline; CT '>=50% decrease in SPD of up to 6 target measurable nodes')
SD
No metabolic response
No Metabolic Response / Stable Disease: on FDG-PET, a Deauville score of 4 or 5 with no significant change in uptake from baseline; on CT, a less-than-50% decrease in the SPD of target lesions from baseline, without meeting any criterion for progressive disease.
PMC4979083 Table 3 'Revised Criteria for Response Assessment', No Response or Stable Disease row (PET 5PS score 4-5 with no significant change from baseline; CT '<50% decrease from baseline in SPD ... no criteria for progressive disease met')
PMD
Progressive metabolic disease
Progressive Metabolic Disease: on FDG-PET, a Deauville score of 4 or 5 with increased uptake intensity from baseline and/or new FDG-avid foci consistent with lymphoma; on CT, an individual node/lesion that grows (e.g. >=50% increase in SPD from nadir with the required absolute size increase) or the appearance of any new lesion.
PMC4979083 Table 3 'Revised Criteria for Response Assessment', Progressive Disease row (PET 5PS score 4-5 with increased intensity from baseline and/or new foci; CT individual node 'Increase by >=50% from PPD nadir' plus absolute size-increase criteria; new lesions)

Histórico de versões

DataEventoDetalheSituação
2014-09-01publishedLugano classification published.confirmado
Quickstart da APIGET /api/v1/systems/luganoaberto
curl -s "https://radcommons.laudos.ai/api/v1/systems/lugano"
Ver documentação completa →